Published in Stat Med on April 01, 1990
Specialized Center of Research in Occupational and Immunologic Lung Disease | NCT00005280
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
The precision of longitudinal lung function measurements: monitoring and interpretation. Occup Environ Med (2005) 0.94
Power and sample size calculations for evaluating mediation effects in longitudinal studies. Stat Methods Med Res (2012) 0.80
A comparison of power analysis methods for evaluating effects of a predictor on slopes in longitudinal designs with missing data. Stat Methods Med Res (2012) 0.78
A Practical and Accurate Approximation for Carrying Out Repeated Measures Power Calculations. Commun Stat Case Stud Data Anal Appl (2016) 0.75